IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
Saved in:
| Title: | IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. |
|---|---|
| Authors: | Hou AJ; Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California, USA., Shih RM; Department of Molecular Biology, University of California, Los Angeles, California, USA., Uy BR; Department of Neurosurgery, University of California, Los Angeles, California, USA., Shafer A; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA., Chang ZL; Department of Molecular Biology, University of California, Los Angeles, California, USA., Comin-Anduix B; Department of Surgery, University of California, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA., Guemes M; Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, California, USA., Galic Z; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.; Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, California, USA., Phyu S; Department of Neurosurgery, University of California, San Francisco, California, USA., Okada H; Department of Neurosurgery, University of California, San Francisco, California, USA.; Parker Institute for Cancer Immunotherapy Center at UCSF, San Francisco, California, USA., Grausam KB; Board of Governor's Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Breunig JJ; Board of Governor's Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Brown CE; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, California, USA., Nathanson DA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA., Prins RM; Department of Neurosurgery, University of California, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California, USA., Chen YY; Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California, USA.; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California, USA.; Parker Institute for Cancer Immunotherapy Center at UCLA, Los Angeles, California, USA. |
| Source: | Neuro-oncology [Neuro Oncol] 2024 Oct 03; Vol. 26 (10), pp. 1850-1866. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication Model: Print Cited Medium: Internet ISSN: 1523-5866 (Electronic) Linking ISSN: 15228517 NLM ISO Abbreviation: Neuro Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1523-5866 |
|---|---|
| DOI: | 10.1093/neuonc/noae126 |
